Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Full Bayesian models for paired RNA-seq data and Bayesian equivalence test

View through CrossRef
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] "In my doctorate research, I have developed Bayesian models to analyze the paired RNAseq data for different types of design. The developed methods are especially of important practice for gene expression analysis using high throughput read-count data. I also proposed and studied a Bayesian test procedure for the equivalence test with parameter margin, which has a wide range of applications in pharmaceutical statistics. In the first part of my dissertation, I presented a full hierarchical Bayesian model (PairedFB) for the paired RNA-seq count data that accounts for variation of treatment effect among pairs and controls the FDR through the posterior expected FDR. The approach was shown to be able to control FDR at nominal levels and obtain slightly higher power than other methods when their actual FDRs are comparable. The real data analysis also indicates the model tends to find more biologically significant genes. In the second part of my dissertation, I extended the Bayesian model in the first part to the differential expression analysis under multiple conditions (e.g., time points, genotype, etc.). Specifically, I developed a Bayesian partitioning model that jointly models all the possible combinations of gene expression status with the use of the "inverse moment nonlocal prior". Furthermore, I modified the posterior expected FDR under the multiple groups situation so that FDR could be controlled for each group of gene expression patterns. I demonstrated that the proposed model is capable of controlling FDR under nominal levels for each combination of expression patterns, and obtaining satisfactory power even when equivalent expression testing is involved. In the last part of my dissertation, I proposed a Bayesian approach to perform the equivalence test with parameter margin. The properties of posterior distribution of parameter of interest were studied and its frequentist properties were evaluated in terms of type I error and power comparing with other frequentist methods. The developed Bayesian test procedure was shown to control type I error close to 5 percent and obtain higher power than currently best frequentist test. Using the example dataset, I demonstrated that the proposed Bayesian test could provide unique and intuitive post-experimental evidence of supporting one hypothesis in addition to reporting the dichotomized decision." --p. 192
University of Missouri Libraries
Title: Full Bayesian models for paired RNA-seq data and Bayesian equivalence test
Description:
[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.
] "In my doctorate research, I have developed Bayesian models to analyze the paired RNAseq data for different types of design.
The developed methods are especially of important practice for gene expression analysis using high throughput read-count data.
I also proposed and studied a Bayesian test procedure for the equivalence test with parameter margin, which has a wide range of applications in pharmaceutical statistics.
In the first part of my dissertation, I presented a full hierarchical Bayesian model (PairedFB) for the paired RNA-seq count data that accounts for variation of treatment effect among pairs and controls the FDR through the posterior expected FDR.
The approach was shown to be able to control FDR at nominal levels and obtain slightly higher power than other methods when their actual FDRs are comparable.
The real data analysis also indicates the model tends to find more biologically significant genes.
In the second part of my dissertation, I extended the Bayesian model in the first part to the differential expression analysis under multiple conditions (e.
g.
, time points, genotype, etc.
).
Specifically, I developed a Bayesian partitioning model that jointly models all the possible combinations of gene expression status with the use of the "inverse moment nonlocal prior".
Furthermore, I modified the posterior expected FDR under the multiple groups situation so that FDR could be controlled for each group of gene expression patterns.
I demonstrated that the proposed model is capable of controlling FDR under nominal levels for each combination of expression patterns, and obtaining satisfactory power even when equivalent expression testing is involved.
In the last part of my dissertation, I proposed a Bayesian approach to perform the equivalence test with parameter margin.
The properties of posterior distribution of parameter of interest were studied and its frequentist properties were evaluated in terms of type I error and power comparing with other frequentist methods.
The developed Bayesian test procedure was shown to control type I error close to 5 percent and obtain higher power than currently best frequentist test.
Using the example dataset, I demonstrated that the proposed Bayesian test could provide unique and intuitive post-experimental evidence of supporting one hypothesis in addition to reporting the dichotomized decision.
" --p.
192.

Related Results

MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Abstract P1-05-23: Utilities and challenges of RNA-Seq based expression and variant calling in a clinical setting
Abstract Introduction Variant calling based on DNA samples has been the gold standard of clinical testing since the advent of Sanger sequencing. The u...
Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLC
Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLC
ABSTRACTCurrently, DNA and RNA are used separately to capture different types of gene mutations. DNA is commonly used for the detection of SNVs, indels and CNVs; RNA is used for an...
Generating Synthetic Single Cell Data from Bulk RNA-seq Using a Pretrained Variational Autoencoder
Generating Synthetic Single Cell Data from Bulk RNA-seq Using a Pretrained Variational Autoencoder
AbstractSingle cell RNA sequencing (scRNA-seq) is a powerful approach which generates genome-wide gene expression profiles at single cell resolution. Among its many applications, i...
Benchmarking Algorithms for Gene Set Scoring of Single-cell ATAC-seq Data
Benchmarking Algorithms for Gene Set Scoring of Single-cell ATAC-seq Data
AbstractGene set scoring (GSS) has been routinely conducted for gene expression analysis of bulk or single-cell RNA-seq data, which helps to decipher single-cell heterogeneity and ...
Abstract 2708: Toward improved cancer classification using PCA + tSNE dimensionality reduction on bulk RNA-seq data
Abstract 2708: Toward improved cancer classification using PCA + tSNE dimensionality reduction on bulk RNA-seq data
Abstract Intro: Minor variations in cancer type can have a major impact on therapeutic effectiveness and on the course of drug research and development. In order to ...
MuSiC2: cell type deconvolution for multi-condition bulk RNA-seq data
MuSiC2: cell type deconvolution for multi-condition bulk RNA-seq data
ABSTRACTCell type composition of intact bulk tissues can vary across samples. Deciphering cell type composition and its changes during disease progression is an important step towa...
Global Prediction of Chromatin Accessibility Using RNA-seq from Small Number of Cells
Global Prediction of Chromatin Accessibility Using RNA-seq from Small Number of Cells
ABSTRACTConventional high-throughput technologies for mapping regulatory element activities such as ChIP-seq, DNase-seq and FAIRE-seq cannot analyze samples with small number of ce...

Back to Top